Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Dapagliflozin and Saxagliptin Fixed Dose Combination in Indian T2D Patients
NCT04445714Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin, saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Apr 2021; status: completed.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04445714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445714.